| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -100,984 | - |
| Depreciation and amortization expense | 131 | - |
| Stock-based compensation expense | 7,826 | - |
| Net amortization of premiums and accretion of discounts on short-term investments | 2,874 | - |
| Non-cash lease expense | 415 | - |
| Accounts receivable | 70 | - |
| Prepaid expenses and other assets | 7,811 | - |
| Accounts payable | -55 | - |
| Accrued expenses and other current liabilities | 1,193 | - |
| Operating lease liabilities | -415 | - |
| Net cash used in operating activities | -102,644 | - |
| Purchases of short-term investments | 347,596 | - |
| Maturities of short-term investments | 195,285 | - |
| Purchases of equipment | 111 | - |
| Net cash used in investing activities | -152,422 | - |
| Payments of deferred offering costs | 34 | - |
| Proceeds from exercises of stock options | 1,372 | - |
| Net cash provided by financing activities | 1,338 | - |
| Restricted cash | - | 194 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -253,728 | - |
| Cash and cash equivalents | - | 45,458 |
| Cash and cash equivalents at beginning of period | 326,086 | - |
| Total cash, cash equivalents and restricted cash at end of period | - | 45,652 |
| Cash and cash equivalents at end of period | 72,358 | - |
Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)